Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
出版年份 2014 全文链接
标题
Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
作者
关键词
-
出版物
Expert Review of Hematology
Volume 7, Issue 2, Pages 255-264
出版商
Informa UK Limited
发表日期
2014-02-14
DOI
10.1586/17474086.2014.876898
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Myeloproliferative neoplasms and thrombosis
- (2013) T. Barbui et al. BLOOD
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia
- (2013) T Barbui et al. LEUKEMIA
- Personalized management of essential thrombocythemia—application of recent evidence to clinical practice
- (2013) A Tefferi et al. LEUKEMIA
- Are MPNs Vascular Diseases?
- (2013) Guido Finazzi et al. Current Hematologic Malignancy Reports
- Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
- (2012) T. Barbui et al. BLOOD
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
- (2012) T. Barbui et al. BLOOD
- Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms
- (2012) Omar Abdel-Wahab et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
- (2012) Véronique Gelsi-Boyer et al. Journal of Hematology & Oncology
- Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture
- (2012) Ayalew Tefferi LEUKEMIA RESEARCH
- The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
- (2012) Umberto Gianelli et al. MODERN PATHOLOGY
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
- (2012) Giovanni Barosi et al. PLoS One
- Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
- (2011) Alessandra Carobbio et al. AMERICAN JOURNAL OF HEMATOLOGY
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis
- (2011) T. Buhr et al. HAEMATOLOGICA
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
- (2011) G Finazzi et al. LEUKEMIA
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
- (2011) A Tefferi et al. LEUKEMIA
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis
- (2010) Maud Brousseau et al. HISTOPATHOLOGY
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Philadelphia Chromosome–Negative Chronic Myeloproliferative Disease
- (2009) Juergen Thiele AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis
- (2009) Kais Hussein et al. EXPERIMENTAL HEMATOLOGY
- JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
- (2009) Alessandra Carobbio et al. EXPERIMENTAL HEMATOLOGY
- Clinical relevance of JAK2 (V617F) mutant allele burden
- (2009) F. Passamonti et al. HAEMATOLOGICA
- Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia
- (2009) Juergen Thiele et al. JOURNAL OF CLINICAL ONCOLOGY
- Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
- (2009) Peter J. Campbell et al. JOURNAL OF CLINICAL ONCOLOGY
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- (2009) A Tefferi et al. LEUKEMIA
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Significance of Bone Marrow Biopsy andJAK2V617FMutation in the Differential Diagnosis Between the “Early” Prepolycythemic Phase of Polycythemia Vera and Essential Thrombocythemia
- (2008) Umberto Gianelli et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
- (2008) F. Passamonti et al. HAEMATOLOGICA
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- (2008) A Tefferi et al. LEUKEMIA
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started